Provided by Tiger Fintech (Singapore) Pte. Ltd.

VYNE Therapeutics Inc.

1.41
-0.0300-2.08%
Post-market: 1.410.00000.00%16:00 EDT
Volume:162.07K
Turnover:229.89K
Market Cap:20.91M
PE:-1.51
High:1.50
Open:1.42
Low:1.37
Close:1.44
Loading ...

Vyne Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
25 Apr

Vyne Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $4.5 From $5.75

THOMSON REUTERS
·
25 Apr

VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell

MT Newswires Live
·
25 Apr

Vyne Therapeutics Inc - Clinical Hold Does Not Affect Phase 2B Trial of Repibresib Gel

THOMSON REUTERS
·
25 Apr

VYNE Therapeutics Provides Update on VYN202 Program

GlobeNewswire
·
25 Apr

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire
·
20 Mar

VYNE Therapeutics Reports Progress in Clinical Trials

TIPRANKS
·
08 Mar

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)

TIPRANKS
·
07 Mar

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
07 Mar

Buy Rating for VYNE Therapeutics Driven by Strong Financial Health and Promising Pipeline Developments

TIPRANKS
·
07 Mar

VYNE Therapeutics: Strong Financials and Promising Clinical Developments Reinforce Buy Rating

TIPRANKS
·
06 Mar

Vyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

VYNE Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $84.000K Miss $140.000K Estimate

Benzinga
·
06 Mar

BRIEF-VYNE Therapeutics FY Revenue USD 501 Thousand

Reuters
·
06 Mar

Vyne Therapeutics FY EPS From Cont Ops USD -0.93

THOMSON REUTERS
·
06 Mar

Vyne Therapeutics FY Net Income USD -39.834 Million

THOMSON REUTERS
·
06 Mar

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

GlobeNewswire
·
06 Mar

EDSA: Raises $15 Million to Advance EB06…

Zacks Small Cap Research
·
03 Mar

Vyne Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Reuters
·
24 Feb

TD Cowen Remains a Buy on VYNE Therapeutics (VYNE)

TIPRANKS
·
20 Feb